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Opinion statement
Central nervous system (CNS)-hemophagocytic lymphohistiocytosis (HLH) is not a disease
in itself, but it is part of a systemic immune response. The vast majority of patients with
CNS-HLH also have systemic HLH and a large number of patients with primary and
secondary HLH have CNS involvement. Reactivations within the CNS are frequent during
the course of HLH treatment and may occur concomitant with or independent of systemic
relapses. It is also important to consider primary HLH as an underlying cause of “unknown
CNS inflammation” as these patients may present with only CNS disease. To initiate proper
treatment, a correct diagnosis must be made. A careful review of the patient’s history and
a thorough neurological examination are essential. In addition to the blood tests required
to make a diagnosis of HLH, a lumbar puncture with cerebrospinal fluid (CSF) analysis and
magnetic resonance imaging (MRI) should always be done in all cases regardless of the
presence or absence of neurological signs or symptom. Treatment options for CNS-HLH
include, but are not limited to, those commonly used in systemic HLH, including cortico-
steroids, etoposide, cyclosporine A, alemtuzumab, and ATG. In addition, intrathecal
treatment with methotrexate and corticosteroids has become a standard care and is likely
to be beneficial. Therapy must be initiated without inappropriate delay to prevent late
effects in HLH. An interesting novel approach is an anti-IFN-gamma antibody (NI-0501),
which is currently being tested. Hematopoietic stem cell transplantation (HSCT) also
represents an important CNS-HLH treatment; patients with primary HLH may benefit from
immediate HSCT even if there is active disease at time of transplantation, though care
should be taken to monitor CNS inflammation through HSCT and treat if needed. Since
CNS-HLH is a condition leading to the most severe late effects of HLH, early expert
consultation is recommended.
Introduction
Hemophagocytic lymphohistiocytosis (HLH) is not
a single disease but rather a clinical syndrome of
life-threatening hyperinflammation. It may result
from genetic defects (primary HLH [1•]) or be
acquired with infectious, neoplastic, autoinflamma-
tory, autoimmune, and immunodeficiency etiolo-
gies (secondary HLH) [1•]. Primary HLH is rare,
with an estimated yearly incidence in Sweden of
0.12–0.15 per 100,000 children [2]. The incidence
of primary HLH in adults or that of secondary
HLH is not studied.
The term “central nervous system (CNS) disease”
is frequently used in the HLH-related literature; but
to date, there is no consensus regarding its definition.
However, most HLH experts agree that an abnormal
CSF and/or MRI of the brain, with or without distinct
neurological signs or symptoms, define CNS-HLH.
Although differences of opinion still exist on how
to define CNS disease, there is agreement that the
term refers to infiltration of activated lymphocytes
and macrophages into the meninges and brain [3].
CNS disease has been divided into three neuropath-
ological stages: stage I with leptomeningeal inflam-
mation, stage II with perivascular infiltration, and
stage III with massive tissue infiltration, blood vessel
destruction, and tissue necrosis. This infiltration can
induce devastating brain lesions in affected patients
and is an important cause of mortality and morbidity
in HLH [4••, 5].
In both primary and secondary HLH, CNS in-
volvement is a frequent finding at disease onset [6–
9]. In addition, disease reactivation, during or after
therapy, occurs frequently in the CNS. Overall, CNS
disease has been reported in 30–73% of all HLH
patients, either at presentation or during the course
of the disease [7, 10, 11••]. As the disease may be
difficult to diagnose, a high index of suspicion is
required when evaluating patients with systemic
HLH. The clinical picture of HLH is similar in prima-
ry and secondary cases and is characterized by sys-
temic inflammation, markedly elevated cytokine lev-
els and immune-mediated organ damage [12, 13••,
14]. HLH is currently diagnosed by either (1) a prov-
en genetic mutation or (2) fulfilling five out of eight
clinical criteria (fever, splenomegaly, cytopenias of at
least two cell lines, hypertriglyceridemia and/or
hypofibrinogenemia, hyperferritinemia, abnormally
low NK-cell activity, high levels of soluble IL-2 recep-
tor, and pathologic evidence of hemophagocytosis in
tissues) [15]. By contrast, the clinical presentation of
CNS disease in HLH is highly variable [8, 16]. Oc-
currence of neurological symptoms is not included as
a diagnostic criterion of HLH, but it is important to
consider HLH in a child with unexplained neurologic
manifestations, especially one with fever, pancytope-
nia, and hepatosplenomegaly.
As survival in patients with HLH has improved
markedly [7, 17], it has become increasingly
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important to thoroughly evaluate long-term sequel-
ae, the most important of which are neurological.
Unfortunately, significant motor and cognitive defi-
cits may occur following HLH [16, 18••]. Early rec-
ognition and prompt treatment of CNS disease may
prevent irreversible CNS injury and are therefore of
greatest importance in order to improve the long-
term outcome [5, 16]. Neurological outcomes after
treatment are, however, unknown as therapy trials
have tended to merely focus on survival.
To recommend the best possible treatment for CNS
involvement, we need to understand the pathophysiol-
ogy of CNS-HLH. It is likely similar to that of systemic
HLH, i.e., massive hyper-inflammation leading to
destruction of brain tissue. Therefore, it is important to
constantly reduce inflammatory HLH activity to prevent
CNS injury. In addition, insufficient cytotoxicity in pri-
mary HLH may result in reduced elimination of virus
infected cells; hence, antiviral therapy should be given
when possible. The HLH therapy is based on specific
immunotherapy and/or chemotherapy regimens fol-
lowed by hematopoietic stem cell transplantation
(HSCT) in primary HLH [7, 15, 17].
Here, we review the available literature on treat-
ment of CNS involvement in HLH, including
mechanisms of action and clinical efficacy. We also
present suggestions regarding treatment of CNS-
HLH.
Definition of CNS Disease in HLH
The definition of CNS disease in HLH has not been standardized. Importantly,
however, retrospective studies suggest that the presence of CNS disease carries
key prognostic significance [19], including higher risk of neurological impair-
ment and future disability as well as higher mortality [16, 19]. This lack of
standardized definitions limits knowledge about response of CNS disease to
therapy. Comparability across cohorts is equally limited for this reason. Eval-
uation for possible CNS involvement in HLH rests on information from three
specific areas of investigation: (a) the presence of neurological signs/symptoms,
(b) neuroimaging abnormalities, and (c) evaluation of CSF. In Table 1, we
outline literature describing the relative frequency of specific findings in the
three above-mentioned categories.
Neurological signs/symptoms
Few studies including prospective neurological evaluations of consecutive HLH
patients exist [7, 10, 16, 23•]. The findings of these and a number of retro-
spective efforts have documented the rate of CNS involvement to be in the
range of 18–73% [4••, 6, 8, 9, 11••, 24••]. The larger and more systematic of
the studies suggest that about 2/3 of all HLH patients (both primary and
secondary) experience neurological manifestations [7, 19]. These numbers rest
on evaluation of cases that, for the most part, present with systemic HLH and
are noted additionally to have CNS features. However, inflammation of the
CNS may be the primary and only clinical presentation of HLH [25–30]. The
prospective treatment study, HLH-2004, will provide some answers to these
questions. This study documents standardized neurological outcomes and is
due to be published in 2016. Preliminary results suggest frequent neurological
involvement in HLH. The study is closed but data is not yet published.
Reported neurological symptoms and/or signs are severe, sometimes life-
threatening, andmay occur early on in the course of the disease. Seizures are the
most common sign of neurological dysfunction, as seen in 33–83% of children
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who are reported to have CNS-HLH [8, 10, 11••, 16, 19, 24••]. Mental status
changes, described variably as irritability, disturbance of consciousness, and
encephalopathy also occur commonly (31–47%), suggesting that gray matter
dysfunction is relatively common in this population. Additionally, meningism
is reported in approximately one third of patients with neurological findings in
some cohorts. Focal neurological signs, such as hemiparesis, cranial neuropa-
thies, and ataxia, are seen in 10–20% of reported cohorts [8, 10, 11••, 16, 19,
24••]. However, comparison between cohorts is difficult due to inconsistency
in the rates of neurological symptoms reported.
The differential diagnosis for CNS-HLH is broad and includes acute
disseminated encephalomyelitis (ADEM), acute necrotizing encephalopa-
thy (ANE), CNS vasculitis, multiple sclerosis, encephalitis, CNS manifes-
tations of rheumatologic disease (such as systemic lupus erythematosus),
and other genetically mediated CNS inflammatory disorders such as
interferonopathies.
Analysis of CSF
CSF abnormalities are seen in a large proportion of HLH cases with or
without neurological symptoms. A lumbar puncture should, therefore, be
routinely performed in all children where there is a suspicion of HLH and
where no contraindications are present. Analysis of CSF should include
standard tests (i.e., cells, protein including fractions, glucose, lactate, and
microbiology) and a cytospin with examination for hemophagocytosis.
CSF pleocytosis is seen in 10–47% of HLH patients [7, 10, 11••, 16,
19]. It should be noted, however, that pleocytosis may be a late sign and
repeat lumbar punctures may be of value if clinical suspicion remains.
Although increased protein levels, as seen in 11–41% of HLH patients [7,
9, 16], are usually only moderately elevated (between 500 and 1000 mg/L,
normal range age-dependent 150–400 mg/L), values up to 10,000 mg/L
have been reported [10, 31]. Protein levels higher than 2500 mg/L have
been associated with stage III abnormalities [4••], but the prognostic value
is uncertain as even patients with extremely elevated levels have had a
good outcome [31]. High CSF protein levels in an encephalopathic child
with unknown diagnosis should raise the suspicion of a neuroinflamma-
tory condition including HLH.
“Abnormal CSF” is defined in many studies as including pleocytosis,
increased CSF protein, or both. This classification leads to findings of CSF
abnormalities in 16–76% of HLH cases [7, 8, 10, 16]. As a whole, the
presence of neurological symptoms and CSF abnormalities of any kind is a
negative prognostic marker, e.g., reducing 5-year survival from 67 to 40%
[7, 16]. CSF abnormalities may respond rapidly to therapy, with one case
series showing resolution of CSF abnormalities in all children within
6 weeks of treatment [10].
Although the pathogenesis of HLH is not fully understood, the clinical
symptoms are considered to be mediated by excessive activation of CD8+
T lymphocytes and the release of cytokines such as tumor necrosis factor-α,
IL-1β, IL-6, IL-8, and interferon-γ [32–35]. Limited information from cases
reports suggests that other neuroinflammatory markers such as neopterin
may be useful for diagnosis of CNS disease [36]. Given similarities with
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other neurological diseases affecting white matter, biomarkers known to be
important for these disorders, e.g., CXCL 13 and neurofilament light chain,
should also be studied in the future [37]. Since neurological symptoms
may be seen in the presence or absence of elevated CSF protein or pleo-
cytosis [12, 15, 16], finding biomarkers with a higher sensitivity and
specificity for CNS HLH would be of great importance.
Hemophagocytosis, which is described to be present in 91% of brain
biopsies, mostly located in the meninges [4••] and in 92% of bone
marrow samples, was less commonly seen in the CSF (39%) of pediatric
cases [7]. Whether the degree of hemophagocytosis in the CSF correlates to
the duration and severity of disease, as demonstrated in brain tissue [4••],
is not known.
Neuroimaging
MRI of the brain with gadolinium is the imaging modality of choice in
situations in which CNS involvement in HLH is suspected (Figs. 1 and 2).
Where MRI is not readily available, CT scans may provide valuable struc-
tural and other information, but cannot replace the detailed assessment
available from MRI. The range of abnormalities seen on neuroimaging is
broad. Descriptive information from retrospective case series including
both primary and secondary forms of HLH suggests that multifocal and
bilateral abnormalities seen on T2-weighted imaging are almost universal-
ly present in primary HLH (89%), with a high rate of symmetric involve-
ment (53%), thus, distinguishing it from ADEM where symmetric involve-
ment is infrequently seen [8]. Furthermore, large, ill-defined, confluent
lesions are seen in up to 2/3 of an HLH population [8]. CNS hemorrhage
was seen in 5/43 cases in one series of mixed primary and secondary HLH [10].
Chronic changes such as atrophy and calcifications are noted in several
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Fig. 1. Suggested workup for CNS disease in a patient with HLH.
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series, but information on timing of the imaging and relation to the use of
agents such as steroids and in relation to onset of symptoms are not available in
these reports [8–10, 38]. Administration of contrast is beneficial
Fig. 2. Neuroradiological MRI findings in HLH. a T2w image showing bilateral hyperintense lesions in the cerebellum. b T2w image
with hyperintense signal and edema in the left posterior hemisphere and abnormalities in the brainstem. c Diffusion weighted
imaging of the same region as in b with lesions imitating cerebral infarction.
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in this population, with one small case series suggesting the presence of nodular
or ring (6/9), and/or leptomeningeal enhancement (5/9) in the majority of
cases [38].
Treatment of CNS HLH
Review of the literature
The available literature offers no consensus on treatment directed at CNS
involvement in HLH. Evidence-based guidelines are lacking and no clinical
trials with a focus specifically on CNS disease have been conducted to date. In
order to identify published cases of CNS HLH and its specific treatment, we
searched the PubMed andMedline databases using the terms “Hemophagocytic
lymphohistiocytosis,” “Familial hemophagocytic lymphohistiocytosis,” or
“Macrophage activating syndrome.” The search included studies of both chil-
dren and adults in the English literature and identified 15 papers focused on
treatment of CNS involvement in HLH (summarized in Table 2). Most articles
were retrospective case reports or case series.
The majority of published reports describe the use of systemic steroids
(primarily dexamethasone) combined with other immunosuppressive thera-
pies (cyclosporine A and etoposide), as in the treatment protocols of HLH-94
and HLH-2004 [7, 15]. Both these protocols used intrathecal treatment weekly
during the induction phase from weeks 3–6 in patients who had clinical
symptoms of CNS disease progression after 2 weeks of systemic treatment, or in
those with worsening or unchanged CSF pleocytosis. The rationale for not using
intrathecal chemotherapy in all children with CNS involvement at therapy start
was that the CNS symptoms improved with systemic therapy alone in most
cases. TheHLH-94 protocol [7] used intrathecalmethotrexate alone whileHLH-
2004 [15] used intrathecal prednisolone in addition. Another option for HLH
treatment is antithymocyte globulin (ATG rabbit) and methylprednisolone
followed by cyclosporine A, which is given until hematopoietic stem cell
transplant (HSCT), generally allowing tapering of methylprednisolone [17]. In
this protocol, patients with CNS disease also receive intrathecal methotrexate
and corticosteroids [17]. As both the definitions of CNS-HLH and the time
points of treatment vary, direct comparison between these treatments is diffi-
cult. The HLH-94 protocol showed that 81/122 (66%) patients with any
neurological involvement at onset of disease were alive and in complete re-
mission at 2 months after start of treatment [7]. This is comparable to the ATG
study [17] which stated that in patients with signs of overt neurologic disease
the probability of achieving complete remission was 11/19 (58%) within a
median time of 1.3 months.
Today, intrathecal methotrexate and corticosteroids (as described in HLH-
2004 [15]) has become standard of care in the initial treatment of children with
CNS-HLH. However, data on the value of intrathecal therapy in patients with
CNS involvement is limited. In the first report on HLH-94, neurological alter-
ations were reported in 35/109 (32%) of the patients at onset. In the 35 affected
individuals, symptoms normalized in 21/31 (67%) survivors after 2 months of
HLH-94 therapy. The rate of normalization was similar whether intrathecal
therapy was used or not as an additional treatment to systemic corticosteroids,
etoposide, and cyclosporin (10/15 versus 10/15, respectively) [45]. However,
intrathecal methotrexate was not studied in a randomized fashion. Hence,
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additional studies will be required to better evaluate the value of intrathecal
therapy in CNS-HLH.
Interestingly, a single report describes treatment with intrathecal rituximab
in post-transplant lymphoproliferative disorder (PTLD) in the CNS, a lym-
phoproliferative disorder with similar features of CNS-HLH. PTLD is a very rare
complication of HSCT. This study described successful treatment of CNS PTLD
with intrathecal rituximab therapy in two children who had failed to respond to
standard chemotherapy, intravenous rituximab and EBV specific cellular ther-
apy [46]. For patients withHLH secondary to EBV-infection, rituximab has been
shown to be beneficial for systemic symptoms [47, 48], but the literature does
not provide specific results on CNS disease in these patients.
Alemtuzumab [49], a monoclonal anti-CD52 antibody, is another option
that has been used for treatment of HLH [44]. This immunotherapy targets B
and T lymphocytes and macrophages. A study on refractory HLH with alemtu-
zumab has yielded promising results [44], but there was a lack of adequate data
to comment fully on the responsiveness of refractory CNS disease. Immuno-
modulating drugs such as IL-1 receptor antagonists have also been used to treat
HLH/MAS with improvements described in case reports [50•, 51] and a case
series with 12 patients [52]. However, data on CNS involvement were not
available in any of these publications.
Two reports suggest that children with CNS HLH can be cured by initiation
of HSCT soon after onset. Successful transplantation may prevent both reacti-
vations and CNS disease progression [39] and may prevent the emergence of
neurological late effects [41], though reactivation of CNS disease may occur
after HSCT.
Ongoing clinical trials
Hybrid immunotherapy for HLH (HIT-HLH, NCT01104025) and Euro-HIT,
two clinical trials utilizing ATG, etoposide, and dexamethasone, recently closed
and results are pending. Overall, the rationale for these trials was the potential
additive or synergistic effects of combining anti-T cell serotherapy (ATG) with
reduced dose-intensity etoposide in order to achieve sustained HLH suppres-
sion while minimizing myelosuppression. Because these trials utilize conven-
tional agents with typical IT therapy in the case of CNS disease, it is not expected
that they will provide new information regarding the treatment of CNS-HLH.
Another ongoing trial combines alemtuzumab, methylprednisone, and cy-
closporine (NCT02472054). The rationale for this trial is based on the T cell
depleting effects of alemtuzumab and prior reports of its activity in HLH [44,
53]. The trial is ongoing and results are not available.
Also ongoing is a trial (NCT01818492) testing a new anti-IFNγmonoclonal
antibody NI-0501 for the treatment of HLH. This therapy represents a new and
targeted approach for treating HLH based on preclinical data from animal
models. Although the trial is ongoing and final results are pending, interim
results were reported in abstract form (https://ash.confex.com/ash/2015/
webprogram/Paper87376.html) in December 2015. This report revealed that
three patients with CNS disease were treated and that two were possible to
evaluate. Both had resolution of CNS signs and symptoms. At this time, it is not
clear how useful NI-0501 will be for CNS-HLH, as results of the trial are still
preliminary and these numbers are very small. Of note, a large drug such as an
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antibody would not ordinarily be expected to cross the blood-brain barrier.
However, inflammation is known to open this barrier in other contexts and this
also may occur in CNS-HLH.
Another very promising agent is the JAK1/2 inhibitor ruxolitinib shown in a
recent study of two murine models of HLH to be effective. In the Rab27a-/-
mice, CNS involvement was significantly reduced with ruxolitinib therapy [54].
To our knowledge, there is so far no clinical trial initiated with ruxolitinib.
Treatment considerations—opinion statement
The first step towards optimal treatment of CNS-HLH is prompt and accurate
diagnosis. Thismeans looking for CNS involvement evenwhen the patient does
not present with obvious signs or symptoms. All patients should receive a brain
MRI and lumbar puncture, including assessment of neuro-inflammatory
markers if available, as soon as this can safely be performed after diagnosis of
HLH. We regard presence of unequivocal neurological symptoms and/or signs,
any abnormality in the CSF or brain MRI compatible with an inflammatory
process to be consistent with a diagnosis of CNS-HLH. Therapy should be
started in all HLH cases with neurological symptoms even if a lumbar puncture
or MRI have not been obtained or results are still pending.
Although the optimal treatment for CNS-HLH is unknown, below, we
present our approach to therapy, which is based on currently available evidence
and/or personal experience. The algorithm in Fig. 1 represents the personal view
of the authors how to approach the HLH patient with CNS disease. The
treatment suggestions in Fig. 1 include HLH patients with genetic and acquired
disease without a known underlying condition such as a malignancy, rheuma-
tologic, or metabolic disease.
A steroid, preferably high-dose dexamethasone, is of importance in CNS-
HLH treatment. Results of preclinical studies have shown that dexamethasone
has a longer half-life in the CSF and better CSF penetration than does predni-
sone [55, 56], and in prospective randomized trials, dexamethasone yielded
better control of CNS leukemia [57]. The highest standard dose of dexameth-
asone in the HLH-94/HLH-2004 protocols is 10 mg/m2 per day, but some
authors have used 20 mg/m2 per day for limited time periods in patients with
severe or refractory CNS-HLH.
Etoposide may be effective in the treatment of CNS-HLH. It has also recently
been shown to be effective in a murine model of autoimmune encephalitis by
selectively attacking activated T cells [58]. Treatment with etoposide at a reduced
dosage (75–100 mg/m2) administered only once a week in combinations with
corticosteroids can be used by in patients with MAS-HLH and CNS disease [59].
Our recommendation is that intrathecalMtx and steroids (as described inHLH-
2004) for CNS-HLH should be used as a first-line therapy. Treatment protocols are
typicallyweekly for at least three doses andpreferably until all CSF indices andCNS
symptoms normalize. Surveillance CSF analyses should be obtained for 2–3weeks
afterwards and later if any symptoms reoccur. Brain MRI’s are typically abnormal
for months after resolution of all other aspect of CNS disease so this should not be
used in isolation for guiding subsequent therapy, unless clearly indicative of newor
worsening problems. A recent case report described the use of intrathecal etoposide
as successful salvage treatment for a patient with breast cancer and leptomeningeal
metastasis [46]. One author also advocates intravenous thiotepa for refractory
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CNS-HLH since it readily crosses the blood brain barrier [60] and also leads to high
drug levels in the CSF. [61, 62]. However, the use of intrathecal therapy for CNS-
HLH is controversial. Because cells infiltrate the brain not only via the meninges
but also via vessels, as seen in multiple sclerosis, some argue that invasive intra-
thecal therapy may not be needed. This is in line with the good response to
systemic therapy alone in highly inflammatory CNS conditions other than HLH.
There are also risks with intrathecal chemotherapy: neurological adverse effects are
well described and may be expected [63]. There are also ongoing concerns regard-
ing intrathecal exposure as a major contributor to CNS late effects in children [64].
However, intrathecal therapymay be necessary in patients in which treatment with
dexamethasone, etoposide, or ATG offers good systemic control of HLH, but does
not control CNS disease. Future studies are required to understand the value and
risks of intrathecal therapy in CNS-HLH.
Even if a patient has responded well to initial therapy of HLH, reactivation of
CNS-HLH by the time of HSCT is common. Early transplant in HLH can halt the
progression of CNS disease [39, 41]. Therefore, even if HLH is still active, an early
transplant should be considered as the risk of late effects ismore severe than the risk
of transplantation. In patients who have CNS involvement pre-transplant, surveil-
lance LP’s after donor engraftment are advisable tomonitor for recurrent/persistent
CSF abnormalities. If CNSHLH recurs/worsens after HSCT, as indicated by clinical
findings or CSF, additional IT and system therapy should be considered. Finally, all
long-term survivors shouldhave longitudinal follow-up for neurological late effects
including cognitive and motor evaluations.
Conclusion
CNS-HLH is a life-threatening condition, often but not always associated with
systemic HLH, for which appropriate clinical, immunological, and radiological
work-up is necessary. Current standard of therapy based on immuno-
chemotherapy followed by HSCT in patients with primary disease leads to
disease control in most, but not all patients. Novel therapeutic approaches are
needed, some of which are currently being explored in ongoing clinical trials.
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